Enveric Biosciences

12/18/2025

Microdose examines how the psychedelics sector is increasingly looking toward non-hallucinogenic compounds and highlights Enveric's development of its neuroplastogen lead candidate, EB-003, which is designed to promote neural plasticity without inducing a psychedelic experience. Read it here: https://bit.ly/44DHi8G

12/17/2025

Nearly 1 billion people experience a neuropsychiatric disorder at some time in their lives, yet current treatments like SSRIs are effective in only about 40% of cases. Enveric is developing EB-003, a novel, non-hallucinogenic neuroplastogen, as a potential new treatment for patients underserved by current options. Learn more: https://bit.ly/3CdEiQ3

12/13/2025

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds https://bit.ly/4a8Vbzc

12/11/2025

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds https://bit.ly/3MuAFiK

12/11/2025

Enveric’s IP expansion for its EVM401 series, along with Delix’s recent FDA clearance for a Phase II trial of DLX-001, signal an exciting new chapter for neuroplastogens, which have the potential to provide the therapeutic benefits of psychedelics without the associated hallucinations. Learn more: https://bit.ly/4oATHkG

How neuroplastogens became the next frontier.

12/10/2025

Our CEO, Joseph Tucker, Ph.D., comments on the Company's new notice of allowance from the USPTO for its EVM301 series of drug candidates. Learn more here: https://bit.ly/4pWXRVe

12/09/2025

Once issued, the compositions claims and methods of use claims covered by Enveric's new U.S. patent will further broaden Company's pipeline by covering additional potential neuroplastogenic non-hallucinogenic molecules and strengthening its potential to target neuropsychiatric and addiction disorders for patients with few other options. Learn more: https://bit.ly/4pWXRVe

12/09/2025

Enveric has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders. For more info, visit: https://bit.ly/4pWXRVe

12/08/2025

Enveric's IP expansion for its EVM401 series of drug candidates along with Delix's recent FDA clearance for a Phase II trial of DLX-001 suggest a growing confidence in non-hallucinogenic neuroplastogens that have the potential to transform how neuropsychiatric disorders are treated. Read more in Microdose here: https://bit.ly/3K0YNZz

12/04/2025

Meditech Today highlights the growing validation and regulatory support for non-hallucinogenic neuroplastogens, which have the potential to make psychedelic-like benefits more practical and clinically accessible for those suffering from neuropsychiatric disorders. Learn more about neuroplastogens, including Enveric’s lead candidate EB-003 here:

How neuroplastogens became the next frontier.

12/04/2025

Enveric will present and participate in the Sachs Associates 9th Annual Neuroscience Innovation Forum on January 11, 2026 during “J.P. Morgan Week 2026” in San Francisco. Additionally, Enveric will attend Biotech Showcase 2026, which is being held from January 12-14, 2026. For details: https://bit.ly/4rBDLkX

12/02/2025

Our CEO, Dr. Joseph Tucker, sat down with Authority Magazine to share his insights on how to best heal the broken mental health system and highlight the potential of Enveric’s lead non-hallucinogenic neuroplastogen EB-003 to provide hope to people suffering from depression and anxiety. Read it here: https://bit.ly/4ooWgXb